Company Overview and News

WCT says higher margin civil works to sustain growth

WCT has an impressive RM5bil order book that includes infrastructure and roadway projects at Tun Razak Exchange (TRX) - Bloomberg

Axiata shares tumble 9% on plunge into red

KUALA LUMPUR: Shares in Axiata Group Bhd plunged 9% in early trade Wednesday after the the telco swung to a loss in the first quarter ended March 31.

UWM net profit more than triples

President and CEO Badrul Feisal said UMW’s automotive sector saw healthy results despite challenges, including intense competition and strict lending guidelines enforced by financial institutions.

Tropicana earnings 71.5% higher in quarter one

Looking forward, Tropicana said that while the industry is expected to remain challenging, the group believes there will still be demand for property in prime locations with attractive pricing.

Strong passenger growth lifts AirAsia X Q1 earnings

KUALA LUMPUR: AirAsia X Bhd posted a net profit of RM41.5mil in the first quarter ended March 31, boosted by higher passenger volume and lower operating cost.

Panasonic up 4% on surprise dividend jump

KUALA LUMPUR: Shares in Panasonic Manufacturing Malaysia Bhd extended their gains today after the company declared a final and special dividend amounting to RM2.33 per share.

Hengyuan shares take a tumble after profits fall

KUALA LUMPUR: Hengyuan Refining Co Bhd fell sharply in early trade Tuesday after the refiner’s earnings showed its quarterly profit had fallen 68%.

Retailers scoop up bargains

PETALING JAYA: While foreign funds dumped more than RM2.5il in local equities following the unexpected outcome of Malaysia’s 14th General Election (GE14), the FBM KLCI has remained buoyant as local institutions and retailers scoop up bargains.

Cahya Mata Sarawak share plunge deemed as overdone

At yesterday’s close of RM1.92, the stock had halved its value since Pakatan Harapan won the general election on May 9.

Ismee resigns from Media Prima

PETALING JAYA: Media Prima Bhd said its independent director Datuk Nasir Ahmad will take over the role of chairman of the company following the resignation of Tan Sri Ismee Ismail.

Hengyuan profit falls to RM86.8mil

The refining company attributed the better revenue to higher average product prices in the current quarter of US$76 per barrel compared with US$65 per barrel in the comparative period.

Kenanga in talks to buy Interpac

PETALING JAYA: Kenanga Investment Bank Bhd has begun talks to acquire the stockbroking business of Inter-Pacific Securities Sdn Bhd in a move that would create one of the largest stockbrokers in the country.

Local funds shore up volatile market

REVIEW: Bursa Malaysia in the post-election week reflected investor sentiment over the polling results with a show of confidence by local institutions keeping the market in good stead.

More vibrant stock market

The first five days of the market since the new Pakatan Harapan government took over has been exciting to say the least.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...